^
    7d
    RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2/3, N=429, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    13d
    CARMEN-GC01: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, Sanofi | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date • Combination therapy • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    16d
    Impact of ABCB1 single-nucleotide variants on early, extremely severe neutropenia induced by paclitaxel/nanoparticle albumin-bound paclitaxel in patients with gastric cancer. (PubMed, Br J Clin Pharmacol)
    The ABCB1 C3435T (rs1045642) TT genotype was significantly associated with early, extremely severe neutropenia in patients receiving paclitaxel/nab-paclitaxel. Evaluating this genotype status may help predict those at increased risk for early, extremely severe neutropenia.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    ABCB1 C3435T • ABCB1 G2677T
    |
    albumin-bound paclitaxel • Cyramza (ramucirumab)
    16d
    RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. (PubMed, J Thorac Oncol)
    In RELAY, OS was not significantly improved with similar long OS durations in both treatment arms.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • TP53 wild-type
    |
    Tagrisso (osimertinib) • erlotinib • Cyramza (ramucirumab)
    17d
    Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. (PubMed, ESMO Open)
    Characterizing unresectable, metastatic, or recurrent GC with positive CLDN18.2 expression and evaluating intratumoral heterogeneity and prognostic implications of various therapeutics help advance treatment strategies and develop new therapies for patients with GC.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • HER-2 positive • CLDN18.2 expression • CLDN1 positive
    |
    VENTANA CLDN18 (43-14A) Assay
    |
    Herceptin (trastuzumab) • paclitaxel • Cyramza (ramucirumab)
    20d
    S1701: Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, SWOG Cancer Research Network | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial primary completion date • Surgery • Metastases
    |
    carboplatin • paclitaxel • Cyramza (ramucirumab)
    27d
    CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Eli Lilly and Company | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    29d
    Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (clinicaltrials.gov)
    P2, N=31, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision, the decision is not related to any safety concern.
    Trial termination • Combination therapy • Checkpoint inhibition • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    30d
    Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. (PubMed, Lancet Oncol)
    Paclitaxel and ramucirumab switch maintenance could be a potential treatment strategy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer who are not eligible for immunotherapy or targeted agents.
    P3 data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    paclitaxel • 5-fluorouracil • capecitabine • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium
    1m
    RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2/3, N=429, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial primary completion date • Metastases
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    1m
    Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2, N=126, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    New P2 trial • Metastases
    |
    paclitaxel • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • bemarituzumab (AMG 552)
    1m
    Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, City of Hope Medical Center
    New P1 trial • Combination therapy
    |
    albumin-bound paclitaxel • Cyramza (ramucirumab)
    1m
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    2ms
    RAMOSE: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Xiuning Le | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab)
    2ms
    Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY). (PubMed, Clin Cancer Res)
    This new neoadjuvant combination of pembrolizumab plus ramucirumab was feasible and anti-VEGF agents may enhance the effects of ICIs.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    2ms
    Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) (clinicaltrials.gov)
    P3, N=490, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Cyramza (ramucirumab)
    2ms
    A Study of IMU-131 (HER-Vaxx) in Combination with Chemotherapy or Pembrolizumab in Patients with Metastatic HER2/neu Over-Expressing Gastric Cancer (nextHERIZON) (clinicaltrials.gov)
    P2, N=7, Completed, Imugene Limited | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Apr 2024
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    PD-L1 expression • HER-2 overexpression • HER-2 expression
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • paclitaxel • Cyramza (ramucirumab) • Her-VAXX
    2ms
    RE: Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). (PubMed, J Natl Cancer Inst)
    No abstract available
    P2 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Erbitux (cetuximab) • Cyramza (ramucirumab) • irinotecan
    2ms
    Ramucirumab-induced ascites with endothelial growth factor receptor mutation-positive non-small cell lung cancer: Two case reports. (PubMed, Respirol Case Rep)
    Patient 1, a 72-year-old man, developed ascites 20 months after erlotinib (ERL) and RAM administration, which resolved after their discontinuation and performing paracentesis. Patient 2, an 83-year-old woman, developed ascites 9 months after ERL and RAM administration, which resolved after RAM discontinuation and furosemide administration. Ramucirumab administration can cause ascites due to increased hepatic sinusoidal pressure. Clinicians should be aware of RAM-induced ascites in patients with NSCLC and should appropriately manage it.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    erlotinib • Cyramza (ramucirumab)
    2ms
    A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) (SWOG-Fall 2024)
    Current sub-studies: S1900E (KRAS) activated on April 2, 2021 and is studying sotorasib (AMG 510) in non-squamous NSCLC...S1900G (EGFR and MET) activated on April 3, 2023 and is studying capmatinib and osimertinib with or without ramucirumab in NSCLC. S1900K (MET exon 14 skipping) activated on December 18, 2023 and is studying tepotinib with or without ramucirumab in NSCLC. S1900J (MET amplification) is opening fall 2024 and is studying amivantamab in NSCLC...One hundred seventy-four (5%) were submitted with the classification of "Other". The most common reasons included: no sub-studies available, patient chose hospice, and patient transferred to different hospital.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion
    |
    FoundationOne® CDx
    |
    Tagrisso (osimertinib) • Lumakras (sotorasib) • Cyramza (ramucirumab) • Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib) • Tabrecta (capmatinib)
    2ms
    A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). (PubMed, J Clin Oncol)
    Ramucirumab plus osimertinib significantly prolonged PFS compared with osimertinib alone in patients with TKI-naïve EGFR-mutant NSCLC. The combination is safe and well tolerated.
    P2 data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab)
    3ms
    LUNG-MAP SUB-STUDY: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2, N=56, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Cyramza (ramucirumab) • Tepmetko (tepotinib)
    3ms
    Acclaim-2: Quaratusugene Ozeplasmid (Reqorsa) in Combination with Pembrolizumab in Previously Treated Non-Small Lung Cancer (clinicaltrials.gov)
    P1/2, N=180, Active, not recruiting, Genprex, Inc. | Trial completion date: Nov 2028 --> Dec 2025 | Trial primary completion date: Nov 2027 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    Keytruda (pembrolizumab) • docetaxel • Cyramza (ramucirumab) • Reqorsa (quaratusugene ozeplasmid)
    3ms
    Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2/3, N=378, Not yet recruiting, SWOG Cancer Research Network
    New P2/3 trial
    |
    docetaxel • Cyramza (ramucirumab) • Libtayo (cemiplimab-rwlc) • Hemady (dexamethasone tablets)
    3ms
    MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
    P1/2, N=410, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Aug 2024 --> Apr 2025
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    HER-2 negative • HER-2 expression
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
    3ms
    A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=164, Completed, Eli Lilly and Company | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • HER-2 overexpression • HER-2 negative
    |
    Verzenio (abemaciclib) • Cyramza (ramucirumab) • merestinib (LY2801653) • lodapolimab (LY3300054) • LY3321367
    3ms
    CAMPFIRE: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (clinicaltrials.gov)
    P2, N=105, Recruiting, Eli Lilly and Company | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    gemcitabine • docetaxel • temozolomide • Verzenio (abemaciclib) • cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    3ms
    Stage IV gastric cancer with microsatellite instability-high achieving long-term survival by gastrectomy after nivolumab as third-line therapy: a case report and literature review. (PubMed, Surg Case Rep)
    We report a patient with highly advanced gastric cancer with peritoneal dissemination, which worsened during second-line therapy and was successfully treated with gastrectomy after nivolumab administration as a third-line therapy. MSI-high gastric cancer is a target that should be actively considered for the administration of ICIs, such as nivolumab, and multidisciplinary treatment combined with chemotherapy and gastrectomy, including conversion surgery, can lead to patients' long-term survival.
    Review • Journal • Microsatellite instability • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • cisplatin • paclitaxel • Cyramza (ramucirumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    3ms
    Surgical indication and management of obstructive colonic metastasis from primary lung adenocarcinoma: report of a case and review of the literature. (PubMed, Surg Case Rep)
    In this case, surgical resection of colonic metastasis from primary lung adenocarcinoma may have contributed to the short-term prognosis as a bridge-to-next available multimodal treatment.
    Review • Journal
    |
    NKX2-1 (NK2 Homeobox 1) • CDX2 (Caudal Type Homeobox 2) • NAPSA (Napsin A Aspartic Peptidase)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed
    3ms
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    3ms
    A Prospective, Single-Arm, Multicenter Phase II Study of Transarterial Interventional Therapy Combined with Sintilimab and Ramucirumab for Advanced Hepatocellular Carcinoma (ChiCTR2400087485)
    P2, N=59, Not yet recruiting, Eastern Hepatobiliary Surgery Hospital; Eastern Hepatobiliary Surgery Hospital
    New P2 trial • Metastases
    |
    Tyvyt (sintilimab) • Cyramza (ramucirumab)
    3ms
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (clinicaltrials.gov)
    P1, N=305, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2026 --> Apr 2027 | Trial primary completion date: Jun 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • ASP2138
    3ms
    A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=100 --> 35 | Trial completion date: May 2026 --> Dec 2024 | Trial primary completion date: Jan 2026 --> Dec 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    docetaxel • Cyramza (ramucirumab) • BGB-15025 • BGB-A445
    3ms
    PLATFORM: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (clinicaltrials.gov)
    P2, N=494, Active, not recruiting, Royal Marsden NHS Foundation Trust | Recruiting --> Active, not recruiting | N=924 --> 494
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Herceptin (trastuzumab) • Imfinzi (durvalumab) • capecitabine • Rubraca (rucaparib) • Cyramza (ramucirumab)
    3ms
    Case series of advanced cancer patients harboring FGFR3-TACC3 fusions detected by comprehensive genomic profiling (ESMO Asia 2024)
    Received 3 cycles of pembrolizumab and enfortumab vedotin...Treatment with Erdafitinib, gemcitabine and cisplatin resulted in a partial response...Pembrolizumab with gemcitabine and cisplatin was administered for 4 cycles, but the disease progressed with liver metastasis...Over one year he received many lines of treatment, including sorafenib, gemcitabine and cisplatin, , ramucirumab, nivolumab, and liposomal doxorubicin, lenvatinib durvalumab, and ramucirumab... In clinical practice, ctDNA or tumor NGS can detect rare and actionable FGFR3-TACC fusions in patients with advanced solid tumors that have progressed on standard therapy. Targeted therapy for such fusions can result in clinical benefit.
    Clinical • PD(L)-1 Biomarker • Metastases
    |
    FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
    |
    FGFR3-TACC3 fusion
    |
    Guardant360® CDx • ACTOnco
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Imfinzi (durvalumab) • gemcitabine • sorafenib • Lenvima (lenvatinib) • Balversa (erdafitinib) • Cyramza (ramucirumab) • Padcev (enfortumab vedotin-ejfv)
    4ms
    Lung-MAP Non-Matched Sub-Study: Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) (clinicaltrials.gov)
    P2 | N=166 | Completed | Sponsor: SWOG Cancer Research Network | Active, not recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Jan 2024
    Trial completion • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed
    4ms
    TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov)
    P2, N=23, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil)
    4ms
    A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial • Metastases
    |
    Tyvyt (sintilimab) • capecitabine • Cyramza (ramucirumab) • oxaliplatin
    4ms
    Acclaim-2: Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (clinicaltrials.gov)
    P1/2, N=180, Active, not recruiting, Genprex, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • docetaxel • Cyramza (ramucirumab) • Reqorsa (quaratusugene ozeplasmid)
    4ms
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (clinicaltrials.gov)
    P1, N=305, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • ASP2138
    4ms
    RAMTAS: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (clinicaltrials.gov)
    P3, N=430, Completed, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial primary completion date: Dec 2023 --> Jul 2024 | Active, not recruiting --> Completed
    Trial completion • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil)
    4ms
    An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Ono Pharmaceutical Co. Ltd
    New P1 trial • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • docetaxel • Cyramza (ramucirumab) • BMS-986310